Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
31 mai 2023 16h01 HE
|
Chimerix, Inc.
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
25 mai 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
04 mai 2023 07h00 HE
|
Chimerix, Inc.
– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – –...
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
27 avr. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
18 avr. 2023 16h01 HE
|
Chimerix, Inc.
Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients Multiple Preclinical Datasets Support Potential of Imipridone Platform DURHAM,...
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
02 mars 2023 07h00 HE
|
Chimerix, Inc.
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma...
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
28 févr. 2023 16h05 HE
|
Chimerix, Inc.
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
23 févr. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
05 janv. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
08 déc. 2022 17h00 HE
|
Chimerix, Inc.
– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis – ...